Crossmark

CalScope: methodology and lessons learned for conducting a remote statewide SARS-CoV-2 seroprevalence study in California using an at-home dried blood spot collection kit and online survey

Crossref DOI link: https://doi.org/10.1186/s12874-024-02245-y

Published Online: 2024-05-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lim, Esther

Mehrotra, Megha L.

Lamba, Katherine

Kamali, Amanda

Lai, Kristina W.

Meza, Erika

Bertsch-Merbach, Stephanie

Szeto, Irvin

Ley, Catherine

Martin, Andrew B.

Parsonnet, Julie

Robinson, Peter

Gebhart, David

Fonseca, Noemi

Tsai, Cheng-ting

Seftel, David

Nicolici, Allyx

Melton, David

Jain, Seema
Funding

Funding for this research was provided by:

Centers for Disease Control and Prevention (6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539, 6NU50CK000539)

State of California
License Information

Text and Data Mining valid from 2024-05-27

Version of Record valid from 2024-05-27
More Information

Article History

Received: 30 August 2023

Accepted: 14 May 2024

First Online: 27 May 2024

Declarations

:

: The CalScope study protocol was reviewed and approved as “Not Research/Exempt” by the Committee for the Protection of Human Subjects for the State of California under the category for Public Health Practice/Surveillance or Emergency Response, which does not require informed consent. The Institutional Review Board of Stanford University also reviewed and approved the use of Stanford’s instance of REDCap. All methods were carried out in accordance with relevant guidelines and regulations.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below